… We report here the results of these subgroup analyses. … of the LACE meta-analyses and
these subgroup analyses had no role in the study design, data collection, data analysis, data …

… with non-squamous non-small-cell lung cancer. Here, we report the efficacy of ABCP or
atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in key patient subgroups. …

… of survival among a large subset of patients with lung cancer, … of the analysis was to investigate
survival in a lung cancer … analysis of a large subgroup of patients with lung cancer and …

… Nearly two-thirds of patients with small-cell lung cancer (SCLC) have extensive-stage (ES) …
outcomes in patients with extensive-stage small-cell lung cancer (ES-SCLC). Based on the …

… 6 [LL6]), or versus gefitinib (250 mg/d; LUX-Lung 7 [LL7]). We report subgroup analyses
according to age, including 65 years or older versus younger than 65 years (preplanned; LL3/…

Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-cell
lung cancer (SNCLC). However, newer data have established a role for pemetrexed in …

… a subgroup analysis of patients in the FLEX study, which enrolled patients with advanced
NSCLC whose tumours expressed epidermal growth factor receptor. Our landmark analysis …

… In this subgroup analysis, we report the primary and secondary endpoints in Japanese
patients. We also report the safety of the trial regimen in Japanese patients and compare it with …

… OS results in LUX-Lung 6 were consistent with those in LUX-Lung 3.26 We performed a
preplanned subgroup analysis of Japanese patients in the LUX-Lung 3 trial to confirm if the …

… Conclusions: Gefitinib survival effect was not restricted to certain subgroups. Some subgroups
had equally better outcomes compared to the overall population on both treatments. No …